45 filings
8-K
KYMR
Kymera Therapeutics Inc
2 May 24
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
7:10am
8-K
KYMR
Kymera Therapeutics Inc
1 Apr 24
Departure of Directors or Certain Officers
7:00am
8-K
KYMR
Kymera Therapeutics Inc
22 Feb 24
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
7:10am
8-K
KYMR
Kymera Therapeutics Inc
5 Jan 24
Kymera Therapeutics Announces Proposed Public Offering
4:11pm
8-K
KYMR
Kymera Therapeutics Inc
4 Jan 24
Regulation FD Disclosure
4:01pm
8-K
zur87phe628
4 Jan 24
STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024
7:08am
8-K
j20khn
2 Nov 23
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
9:15am
8-K
543ysgbirj8a5ry
2 Nov 23
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
7:10am
8-K
zbvv9qjvk9an2
3 Aug 23
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
7:10am
8-K
mthy99c764x cbc6
16 Jun 23
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
hzttx
22 May 23
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
4:45pm
8-K
9i6nhpif93e1pitl0wzl
4 May 23
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
7:10am
8-K
ta1vm3 5cqg
10 Mar 23
Regulation FD Disclosure
5:30pm
8-K
6gnnb f9tixyx
27 Feb 23
Departure of Directors or Certain Officers
5:22pm
8-K
c8n6bi6y2v74asia6z
23 Feb 23
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
7:11am
8-K
x9eggkq 1v3t
10 Jan 23
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution
7:06am
8-K
6jqbjo ia09o
14 Dec 22
Regulation FD Disclosure
9:27am
8-K
1xeelbxqnkuuu
14 Dec 22
Regulation FD Disclosure
7:16am
8-K
94otyzkpas64x63z
3 Nov 22
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
7:17am
8-K
1ew2x ifsnkwxpi
13 Oct 22
Regulation FD Disclosure
4:36pm